1. Home
  2. SLNH vs OGEN Comparison

SLNH vs OGEN Comparison

Compare SLNH & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

N/A

Current Price

$1.29

Market Cap

174.8M

Sector

Technology

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

N/A

Current Price

$0.82

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLNH
OGEN
Founded
1961
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.8M
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLNH
OGEN
Price
$1.29
$0.82
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
5.5M
93.8K
Earning Date
11-17-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,782,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$42.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.82
52 Week High
$5.14
$18.90

Technical Indicators

Market Signals
Indicator
SLNH
OGEN
Relative Strength Index (RSI) 37.73 32.48
Support Level $1.78 $0.85
Resistance Level $2.29 $0.99
Average True Range (ATR) 0.27 0.06
MACD -0.00 0.00
Stochastic Oscillator 1.99 0.10

Price Performance

Historical Comparison
SLNH
OGEN

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: